Cognetivity Neurosciences Announces Collaboration with Alzheimer's Society to Further Expand its AI Algorithms

Filament Health Announces Interim Results From Phase I Clinical Trial At The University Of California San Francisco

Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study

MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy

Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital

Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder

Optimi Health Granted Natural Health Product Site Licence By Health Canada

Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease

Clearmind Medicine Announces Clinical Supply Agreement for its Upcoming Clinical Trial

Albert Labs Receives preliminary acceptance of 35 Novel Inventive Claims for Patent Protected Manufacturing Technology

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company

Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial